Ocular Therapeutix, Inc. (OCUL) financial statements (2022 and earlier)

Company profile

Business Address 24 CROSBY DRIVE
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments164,164228,05754,43754,06241,53868,145105,064
Cash and cash equivalents164,164228,05754,43754,06241,53832,93630,784
Short-term investments     35,20974,280
Receivables21,13512,2522,548201226250193
Inventory, net of allowances, customer advances and progress billings1,2501,201954217122113134
Inventory1,2501,201954217122113134
Deferred costs    108  
Other undisclosed current assets4,7514,6502,2311,7131,3451,3901,592
Total current assets:191,300246,16060,17056,19343,33969,898106,983
Noncurrent Assets
Operating lease, right-of-use asset4,8675,8446,655
Property, plant and equipment6,9568,09510,15110,23610,4783,3133,095
Restricted cash and investments1,7641,7641,7646,6141,6141,728228
Total noncurrent assets:13,58715,70318,57016,85012,0925,0413,323
TOTAL ASSETS:204,887261,86378,74073,04355,43174,939110,306
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities24,71317,01610,9039,1597,8816,7515,336
Accounts payable4,5922,7093,2682,9653,5712,1161,957
Accrued liabilities20,12114,3077,6356,1944,3104,6353,379
Debt 8,2901,126 5,5451,549 
Deferred revenue and credits  42
Other undisclosed current liabilities1,6241,358     
Total current liabilities:26,33726,66412,0299,15913,4268,3005,378
Noncurrent Liabilities
Long-term debt and lease obligation57,35948,79158,21724,78812,47114,09415,272
Long-term debt, excluding current maturities51,43541,24349,31224,78812,47114,09415,272
Operating lease, liability5,9247,5488,905
Liabilities, other than long-term debt33,192110,31312,1243,2213,38753768
Deferred revenue and credits3,2213,38753768
Deferred revenue13,00012,000 
Derivative instruments and hedges, liabilities20,19298,31312,124    
Total noncurrent liabilities:90,551159,10470,34128,00915,85814,63115,340
Total liabilities:116,888185,76882,37037,16829,28422,93120,718
Stockholders' equity
Stockholders' equity attributable to parent87,99976,095(3,630)35,87526,14752,00889,588
Common stock8854332
Additional paid in capital633,795615,338379,980333,114263,409225,889218,830
Accumulated other comprehensive loss     (5)(68)
Accumulated deficit(545,804)(539,251)(383,615)(297,243)(237,265)(173,879)(129,176)
Total stockholders' equity:87,99976,095(3,630)35,87526,14752,00889,588
TOTAL LIABILITIES AND EQUITY:204,887261,86378,74073,04355,43174,939110,306

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues43,52217,4034,2271,9901,9231,8871,750
Revenue, net1,9231,8871,750
Cost of revenue(4,407)(2,083)(2,325)(465)(457)(443)(319)
Cost of goods and services sold(4,406)(2,083)(2,325) (457)(443)(319)
Gross profit:39,11515,3201,9021,5251,4661,4441,431
Operating expenses(117,152)(78,167)(87,704)(60,643)(63,389)(44,770)(39,947)
Other undisclosed operating income      319
Operating loss:(78,037)(62,847)(85,802)(59,118)(61,923)(43,326)(38,197)
Nonoperating income (expense)71,484(92,789)(570)(860)(1,463)(1,377)(1,551)
Investment income, nonoperating331681,229879424304166
Interest and debt expense(6,671)(6,768)(6,101)(1,739)(1,892)(1,680)(1,724)
Loss before gain (loss) on sale of properties:(13,224)(162,404)(92,473)(61,717)(65,278)(46,383)(41,472)
Other undisclosed net income6,6716,768178,8451,739   
Net income (loss):(6,553)(155,636)86,372(59,978)(65,278)(46,383)(41,472)
Other undisclosed net income (loss) attributable to parent  (172,744) 1,8921,6801,724
Net loss available to common stockholders, basic:(6,553)(155,636)(86,372)(59,978)(63,386)(44,703)(39,748)
Interest on convertible debt4,409      
Dilutive securities, effect on basic earnings per share(78,121)      
Net loss available to common stockholders, diluted:(80,265)(155,636)(86,372)(59,978)(63,386)(44,703)(39,748)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(6,553)(155,636)86,372(59,978)(65,278)(46,383)(41,472)
Comprehensive income (loss):(6,553)(155,636)86,372(59,978)(65,278)(46,383)(41,472)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (172,744) 1,8971,7431,656
Comprehensive loss, net of tax, attributable to parent:(6,553)(155,636)(86,372)(59,978)(63,381)(44,640)(39,816)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: